Epithelial delay, pain are concerns with new NSAID

Article

Fort Lauderdale, FL-Administration of nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) for epithelial healing and pain control resulted in delayed healing in patients who had undergone surface ablation, according to a report by Marguerite B. McDonald, MD, FACS, and William Trattler, MD, that was presented at the annual meeting of the Association for Research and Vision in Ophthalmology.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.